PB 70 of 2020
National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 6)
I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health make the following determination.
Dated 30 july 2020
Nikolai Tsyganov
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
2 Commencement
3 Authority
4 Schedule
Schedule 1—Amendments 2
National Health (Continued Dispensing - Emergency Measures) Determination 2020 2
(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.6).
(2) This instrument may also be cited as PB 70 of 2020.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 August 2020. |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 89A(3) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Continued Dispensing – Emergency Measures) Determination 2020
[1] Schedule 1, after entry for Entacapone
insert:
Entrectinib | Capsule 200 mg | Oral |
[2] Schedule 1, after entry for Loperamide
insert:
Lorlatinib | Tablet 25 mg | Oral |
| Tablet 100 mg | Oral |
[3] Schedule 1, entry for Metformin
substitute:
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral |
| Tablet containing metformin hydrochloride 850 mg | Oral |
| Tablet containing metformin hydrochloride 1 g | Oral |
| Tablet (extended release) containing metformin hydrochloride 500 mg | Oral |
| Tablet (extended release) containing metformin hydrochloride 1 g | Oral |
| Tablet (prolonged release) containing metformin hydrochloride 500 mg | Oral |
[4] Schedule 1, entry for Salbutamol
substitute:
Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation |
| Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation |
| Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation |
| Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation |
| Oral solution 2 mg (as sulfate) per 5 mL, 150 mL | Oral |
| Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth |
| Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth |
| Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth |
[5] Schedule 1, after entry for Sterculia with frangula bark
insert:
Stiripentol | Capsule 250 mg | Oral |
| Capsule 500 mg | Oral |
| Powder for oral suspension 250 mg | Oral |
| Powder for oral suspension 500 mg | Oral |